Chugai Pharmaceutical is conducting a phase one interventional ‘basket’ study to investigate the safety, tolerability, and efficacy of RAY121, an inhibitor of the classical complement pathway in the immune system. Participants are eligible for this study if they have at least one of the following autoimmune conditions: antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), or immune thrombocytopenia (ITP).
Participants must be between the ages of 18-75 years. For those with ITP, having a platelet count less than 30,000 is another requirement for study participation.
USA, Australia, Austria, Bulgaria, Canada, Croatia, Czechia, France, Germany, Hungary, Italy, Japan, Netherlands, Norway, Poland, Portugal, Romania, Spain, Taiwan, and Turkey
Actively Recruiting